Curis, Inc.

Good morning and welcome to QRIS's third quarter 2023 business update call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero after the company's prepared marks. All participants will have an opportunity to ask questions. To ask a question, you may press star followed by one on your touchtone phone. To withdraw your question, simply press star followed by two. Please note that this event is being recorded. I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer. Diantha, please go ahead.

Thank you, and welcome to Curis' third quarter 2023 business update call. Before we begin, I'd like to encourage everyone to go to the investor section of our website at www.cures.com to find our third quarter 2023 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Denser, President and Chief Executive Officer, and Jonathan Zung, our Chief Development Officer. We will also be available for a question and answer period at the end of our call. I'd now like to turn the call over to Jim.

Thank you, Dantha. Good morning, everyone, and welcome to QRIS's third quarter business update call. This quarter marked a key inflection point for the company. and for patients as we were able to return our focus to clinical enrollment in our Take Aim Leukemia and Take Aim Lymphoma studies with the removal of the partial clinical hold. Later this morning, abstracts for the 65th ASH annual meeting will be unveiled, and we are pleased to have several abstracts under consideration. At ASH, we expect to provide an update from our Take Aim Lymphoma study including our first look at proof of concept data for patients with primary CNS lymphoma, a rare form of extranodal non-Hodgkin lymphoma for which there are limited treatment options. In the Take Aim Leukemia study, we have reopened our clinical sites and are working with them to identify and enroll new patients. As a reminder, the Take Aim Leukemia study is a monotherapy study targeting patients with relapsed or refractory AML with either a FLT3 or spliceosome mutation. Enrollment of new patients has begun, and we expect to have our first look at data from these patients in the first half of 2024. Lastly, we are working with clinical sites and regulatory authorities on advancing a new triplet study of emavucirtib in combination with azacitidine and venetoclax in AML. This study is intended to evaluate safety as well as emavucirtib's ability to enhance the effectiveness of azacitidine and venetoclax by studying AML patients who are responding to azacitidine and venetoclax treatment but still have minimal residual disease or MRD. Our hope is that with the addition of emavucirtib to their treatment regimen, we can help these patients convert from MRD positive status to MRD negative. We expect to initiate this study in the fourth quarter and see initial data in the second half of next year. In short, we're making great progress in advancing the potential of emavucirtib as a monotherapy, as a doublet therapy combining with ibrutinib, and as a triplet therapy in combination with azazitidine and venetoclax, all of which should have data over the coming four quarters. We look forward to providing those updates. With that, I'll turn the call back over to Diantha to review our financial results for the quarter. Diantha?